AstraZeneca PLC
AZN
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
E: ir@astrazeneca.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
Stocks News & Analysis
markets
What are emerging and frontier markets?
Power blocs, frontier stocks and investor shocks explained as the world becomes more complex
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks
Best international companies to own: 2023 Edition
These companies from various corners of the globe are well positioned for the future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,961.70 | 8.20 | -0.10% |
| CAC 40 | 7,329.97 | 5.43 | -0.07% |
| DAX 40 | 21,311.02 | 57.32 | 0.27% |
| Dow JONES (US) | 40,196.62 | 172.34 | -0.43% |
| FTSE 100 | 8,275.60 | 26.48 | 0.32% |
| HKSE | 21,056.98 | 409.29 | -1.91% |
| NASDAQ | 16,475.97 | 347.20 | -2.06% |
| Nikkei 225 | 33,920.40 | 347.14 | -1.01% |
| NZX 50 Index | 12,067.92 | 56.58 | 0.47% |
| S&P 500 | 5,334.55 | 62.08 | -1.15% |
| S&P/ASX 200 | 7,758.90 | 2.80 | -0.04% |
| SSE Composite Index | 3,276.00 | 8.34 | 0.26% |